Tuberculosis has been treatable for decades, which sounds tidy until you learn the standard drug-susceptible TB regimen has long taken at least 6 months. Six. Months. For an infection caused by one bacterium. A bacterium, to be fair, that behaves like it read the employee handbook and found every loophole.
That basic tension sits at the center of a new review by Natalie Waller and Kyu Rhee. Their point is not just "we need better drugs." It is "we need to understand why the old ones work the way they do, why they still need so much time, and why some combinations shine while others fizzle" (Waller and Rhee, 2025).
TB is caused by Mycobacterium tuberculosis, a pathogen with a waxy cell wall, slow growth, and a talent for hiding out in lung lesions called granulomas. Think of granulomas as the immune system's attempt to build a containment fence. Noble effort. Slight problem: the fence can become a bizarre neighborhood with low oxygen, patchy blood flow, stressed bacteria, and lousy drug penetration. If this were a rental listing, it would say "rustic," "full of character," and "actively hostile to modern therapy."
Why 6 Months Is Not Just Bureaucratic Sadism
Older TB treatment was built empirically. Translation: doctors and researchers tested combinations, watched what happened, and learned the hard way that one drug is a great way to breed resistance. So combination therapy became the rule.
Over time, the field also learned something subtler. TB treatment length is not explained by raw antibiotic power alone. Some bacteria divide quickly and die quickly. Others slow down, tuck themselves into hard-to-reach lesions, and become much harder to clear. Waller and Rhee argue that regimen success depends on pharmacology, lesion biology, and bacterial persistence, not just whether a drug looks scary in a petri dish (Waller and Rhee, 2025).
That helps explain the maddening reality of TB care: you can make patients feel better well before you can confidently stop treatment. The bug is like a movie villain who fell off a building in act two. Is it over? Probably not. Keep rolling.
Plot Twist: Shorter Regimens Are Finally Real
This is where things get interesting enough to make even guideline writers loosen their tie.
In 2021, a major trial showed that a 4-month rifapentine-moxifloxacin-based regimen for drug-susceptible pulmonary TB was noninferior to the old 6-month standard in eligible patients (Dorman et al., 2021). That was a big deal because TB's idea of "short course" has long felt like a prank.
For drug-resistant TB, the leap may be even more dramatic. In 2022, the TB-PRACTECAL trial found that a 24-week all-oral regimen using bedaquiline, pretomanid, linezolid, and moxifloxacin outperformed much longer standard care for rifampin-resistant disease, with a better safety profile (Nyang'wa et al., 2022). In other words, fewer months, fewer misery points, better outcomes. Science occasionally does know how to pick up the pace.
By August 23, 2024, WHO had issued a rapid communication highlighting newer 6-month and 9-month options for eligible drug-resistant TB patients, while keeping BPaLM or BPaL as prioritized choices for many cases (WHO, 2024). Then, on December 31, 2024, updated ATS/CDC/ERS/IDSA guidance was published, and CDC highlighted it on January 8, 2025, emphasizing shorter all-oral regimens for both drug-susceptible and drug-resistant TB (Saukkonen et al., 2025).
The Real Endgame: Stop Guessing, Start Designing
The biggest idea in this paper is not nostalgia for TB's treatment history. It is the push to move from empiricism toward rational regimen design.
That means asking sharper questions. Which drugs reach the ugliest lesions? Which combinations kill bacteria in different physiological states? Which regimens are "forgiving" if life gets messy and a patient misses doses? Because life does get messy. TB does not mostly strike people with unlimited sick leave, private transport, and a personal pharmacist named Trevor.
Recent work on target regimen profiles makes this explicit: the ideal TB regimen should be shorter, safer, easier to deliver, and resilient in the real world, not just elegant in a trial slide deck (Lienhardt et al., 2024).
If these mechanism-based ideas hold up, the payoff is enormous. Faster cures. Less resistance. Better adherence. Fewer people stuck choosing between finishing therapy and keeping a job. Not bad for a field that spent many years looking like it was trying to win a Formula 1 race on a lawn mower.
References
-
Waller NJE, Rhee KY. From Empirical Discovery to Targeted Therapy: The Evolution of Tuberculosis Treatment. Cold Spring Harb Perspect Med. 2025. DOI: 10.1101/cshperspect.a041821. PubMed: 42045064
-
Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705-1718. DOI: 10.1056/NEJMoa2033400. PubMed: 33951360
-
Nyang'wa BT, Berry C, Kazounis E, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331-2343. DOI: 10.1056/NEJMoa2117166. PubMed: 36546625
-
Saluzzo F, Adepoju VA, Duarte R, Lange C, Phillips PPJ, on behalf of the UNITE4TB Consortium. Treatment-shortening regimens for tuberculosis: updates and future priorities. Breathe (Sheff). 2023;19(3):230028. DOI: 10.1183/20734735.0028-2023. PMCID: PMC10567072
-
Lienhardt C, Dooley KE, Nahid P, et al. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024;102(8):554-562. DOI: 10.2471/BLT.24.291881. PMCID: PMC11276158
-
Saukkonen JJ, Duarte R, Munsiff SS, et al. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2025;211(1):15-33. DOI: 10.1164/rccm.202410-2096ST. PMCID: PMC11755361
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.